Abstract
Ribonucleotide reductase subunit R2 regulates catalytic action of the enzyme to provide DNA synthesis material via reduction. It has been continuously investigated as anticancer drug target for design and discovery of its inhibitors. Present studies aim to design novel heterocyclic/aryl substituted and adamantyl added thiosemicarbazones out fitted with improved cell permeability and effective RNR inhibition. Design strategy renders significant use of virtual screening and molecular docking studies to converge search of selective molecules for synthesis and further experimental studies. Selected candidates were synthesized and evaluated in vitro for their RNR inhibitory activity (IC50, uM) on MCF-7 cells, breast cancer cell lines. Molecular docking results (docking scores) and experimental results (IC50, uM) were found to be correlated and in agreement. Structure-based and ligandbased studies of results substantiate regulative role of water molecules at catalytic site (H2O: 2057) as well as at RNR inhibitor binding site (H2O: 2023, 2047, 2060 and 2070). Admantyl group has testified constant spatial position in docked poses and involved in steric interactions with Cys271, Asp272, Phe237, Gly234 and Val238. Heterocyclic/aryl substitutions equally offered H-bonds with water molecules (H2O: 2028, 2054, 2061 and 2073) along with amino acids Ser264, Asp272, Tyr324 and Asn346. Present efforts to design new inhibitors incur new characteristics in RNR Inhibition.
Keywords: Ribonucleotide reductase (RNR) inhibitors, Anticancer, Heterocyclic/aryl substituted thiosemicarbazones, Virtual screening, Computational design, Molecular docking.
Current Topics in Medicinal Chemistry
Title:Design and Virtual Screening Towards Synthesis of Novel Substituted Thiosemicarbozones as Ribonuleotide Reductase (RNR) Inhibitors with Improved Cellular Trafficking and Anticancer Activity
Volume: 15 Issue: 1
Author(s): Niharika Gokhale, Sanjay Jain and Mukesh Yadav
Affiliation:
Keywords: Ribonucleotide reductase (RNR) inhibitors, Anticancer, Heterocyclic/aryl substituted thiosemicarbazones, Virtual screening, Computational design, Molecular docking.
Abstract: Ribonucleotide reductase subunit R2 regulates catalytic action of the enzyme to provide DNA synthesis material via reduction. It has been continuously investigated as anticancer drug target for design and discovery of its inhibitors. Present studies aim to design novel heterocyclic/aryl substituted and adamantyl added thiosemicarbazones out fitted with improved cell permeability and effective RNR inhibition. Design strategy renders significant use of virtual screening and molecular docking studies to converge search of selective molecules for synthesis and further experimental studies. Selected candidates were synthesized and evaluated in vitro for their RNR inhibitory activity (IC50, uM) on MCF-7 cells, breast cancer cell lines. Molecular docking results (docking scores) and experimental results (IC50, uM) were found to be correlated and in agreement. Structure-based and ligandbased studies of results substantiate regulative role of water molecules at catalytic site (H2O: 2057) as well as at RNR inhibitor binding site (H2O: 2023, 2047, 2060 and 2070). Admantyl group has testified constant spatial position in docked poses and involved in steric interactions with Cys271, Asp272, Phe237, Gly234 and Val238. Heterocyclic/aryl substitutions equally offered H-bonds with water molecules (H2O: 2028, 2054, 2061 and 2073) along with amino acids Ser264, Asp272, Tyr324 and Asn346. Present efforts to design new inhibitors incur new characteristics in RNR Inhibition.
Export Options
About this article
Cite this article as:
Gokhale Niharika, Jain Sanjay and Yadav Mukesh, Design and Virtual Screening Towards Synthesis of Novel Substituted Thiosemicarbozones as Ribonuleotide Reductase (RNR) Inhibitors with Improved Cellular Trafficking and Anticancer Activity, Current Topics in Medicinal Chemistry 2015; 15 (1) . https://dx.doi.org/10.2174/1568026615666150112110211
DOI https://dx.doi.org/10.2174/1568026615666150112110211 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis
Anti-Cancer Agents in Medicinal Chemistry Pharmaceutical Targeting of the Brain
Current Pharmaceutical Design The Expression, Function and Targeting of Haem Oxygenase-1 in Cancer
Current Cancer Drug Targets Reversing Aberrant Methylation Patterns in Cancer
Current Medicinal Chemistry The Ubiquitin-Proteasome System as a Prospective Molecular Target for Cancer Treatment and Prevention
Current Protein & Peptide Science Chemistry of Tumour Targeted T1 Based MRI Contrast Agents
Current Topics in Medicinal Chemistry Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets Gallic Acid and Gallic Acid Derivatives: Effects on Drug Metabolizing Enzymes
Current Drug Metabolism Disseminated Intravascular Coagulation in Leukemia and Sepsis
Vascular Disease Prevention (Discontinued) Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders
Mini-Reviews in Medicinal Chemistry Ligand-Targeted Liposomes for Cancer Treatment
Current Drug Delivery Zoledronate Induced Hypocalcemia and Hypophosphatemia in Osteoporosis: A Cause of Concern
Current Drug Safety Protein Microarrays for Studies of Drug Mechanisms and Biomarker Discovery in the Era of Systems Biology
Current Pharmaceutical Design Is There a Role for Cytokine Based Therapies in Fibromyalgia
Current Pharmaceutical Design Synergic Study of α-Glucosidase Inhibitory Action of Aloin and its Antioxidant Activity with and without Camel β-Casein and its Peptides
Protein & Peptide Letters Strategy of Computer-Aided Drug Design
Current Drug Targets - Infectious Disorders FK506-Binding Proteins and Their Diverse Functions
Current Molecular Pharmacology PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
Current Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences Novel Platelet Signalling Pathways Identified via Proteomics
Current Proteomics